TREACE MEDICAL CONCEPTS, INC. TMCI 深 滬
已收盤 09-05 16:00:00 美东时间
7.17
0.000
0.00%
華盛通- 最 高7.31
- 今 開7.21
- 成交量 25.22万股
- 最 低 7.01
- 昨 收 7.17
- 總市值 4.51亿
- 52周最高 10.79
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 4.54
- 委 比 13.07%
- 總股本 6290.50万
- 歷史最高 37.17
- 量 比 0.81
- 振 幅 4.18%
- 歷史最低 3.92
- 每 手 1
- 風險率 3.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $8
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $6.6 to $8.
09-04 20:27
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Treace Medical Concepts Affirms FY2025 Sales Guidance of $224.000M-$230.000M vs $227.030M Est
Treace Medical Concepts (NASDAQ:TMCI) affirms FY2025 sales outlook from $224.000 million-$230.000 million to $224.000 million-$230.000 million vs $227.030 million estimate.
08-08 04:14
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Treace Medical Concepts Announces Peer-Reviewed Publication Of The Four-Year Interim Results From Its Align3d Multicenter Prospective Study Demonstrating Clinical And Radiographic Outcomes Of The Lapiplasty Procedure In The Journal Of Foot & Ankle Surgery
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced
08-06 04:34
Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study
Treace Medical Concepts announced the publication of four-year interim results from its ALIGN3D™ study, showcasing positive outcomes of the Lapiplasty® Procedure for hallux valgus. Results include early return to weight-bearing (7.7 days), low recurrence rates (0.8% HVA>20°), and significant pain reduction (81%) and functional improvement (89%) in patients.
08-05 20:05
Treace to Report Second Quarter 2025 Financial Results on August 7, 2025
<p>Treace Medical Concepts, Inc., a medical technology company, announced it will release second-quarter 2025 financial results on August 7, 2025. A conference call to discuss the results will be held at 4:30 pm ET. Interested investors can register to join the call. The company, which focuses on advanced surgical treatments for bunions and midfoot deformities, also provides updates on its innovative medical devices and systems on its investor re...
07-24 20:05
Treace Medical Concepts Files Patent Infringement Lawsuit Against Zimmer Biomet And Paragon 28, Alleging Violation Of 4 Patents Related To Its Lapiplasty 3D Bunion Correction Technologies And Seeking Injunctive Relief And Damages
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its
06-06 01:05
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
<p>Treace Medical Concepts filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc., alleging infringement of four patents related to its Lapiplasty® 3D Bunion Correction® technologies. The case, filed in the U.S. District Court for the District of Delaware, seeks injunctive relief and damages. John T. Treace, the company's chairman, CEO, and founder, emphasized the importance of protecting their intellectual property to safeguar...
06-05 17:00
TMCI Lawsuit Alert! Class Action Lawsuit Against Treace Medical Concepts
Aclass actionlawsuit was filed againstTreace Medical Concepts...
05-23 20:10
